BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 15059917)

  • 1. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects.
    Jackson JG; St Clair P; Sliwkowski MX; Brattain MG
    Cancer Res; 2004 Apr; 64(7):2601-9. PubMed ID: 15059917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
    Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
    Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB; Hynes NE; Lane HA
    Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
    Lee H; Akita RW; Sliwkowski MX; Maihle NJ
    Cancer Res; 2001 Jun; 61(11):4467-73. PubMed ID: 11389077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells.
    Venkateswarlu S; Dawson DM; St Clair P; Gupta A; Willson JK; Brattain MG
    Oncogene; 2002 Jan; 21(1):78-86. PubMed ID: 11791178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the Grb2-associated binder 1/SHP-2 interaction in cell growth and transformation.
    Holgado-Madruga M; Wong AJ
    Cancer Res; 2004 Mar; 64(6):2007-15. PubMed ID: 15026337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent.
    Carón RW; Yacoub A; Zhu X; Mitchell C; Han SI; Sasazuki T; Shirasawa S; Hagan MP; Grant S; Dent P
    Mol Cancer Ther; 2005 Feb; 4(2):243-55. PubMed ID: 15713896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
    Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.
    Martín-Orozco RM; Almaraz-Pro C; Rodríguez-Ubreva FJ; Cortés MA; Ropero S; Colomer R; López-Ruiz P; Colás B
    Neoplasia; 2007 Aug; 9(8):614-24. PubMed ID: 17898861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells.
    Lim SJ; Lopez-Berestein G; Hung MC; Lupu R; Tari AM
    Oncogene; 2000 Dec; 19(54):6271-6. PubMed ID: 11175341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of beta1-integrin function by epidermal growth factor and heregulin-beta has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase.
    Adelsman MA; McCarthy JB; Shimizu Y
    Mol Biol Cell; 1999 Sep; 10(9):2861-78. PubMed ID: 10473632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells.
    Badache A; Hynes NE
    Cancer Res; 2001 Jan; 61(1):383-91. PubMed ID: 11196191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
    Lenferink AE; Busse D; Flanagan WM; Yakes FM; Arteaga CL
    Cancer Res; 2001 Sep; 61(17):6583-91. PubMed ID: 11522658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis.
    Tyagi A; Agarwal R; Agarwal C
    Oncogene; 2003 Mar; 22(9):1302-16. PubMed ID: 12618755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors.
    Klinger M; Farhan H; Just H; Drobny H; Himmler G; Loibner H; Mudde GC; Freissmuth M; Sexl V
    Cancer Res; 2004 Feb; 64(3):1087-93. PubMed ID: 14871842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone-induced phosphorylation of epidermal growth factor (EGF) receptor in 3T3-F442A cells. Modulation of EGF-induced trafficking and signaling.
    Huang Y; Kim SO; Jiang J; Frank SJ
    J Biol Chem; 2003 May; 278(21):18902-13. PubMed ID: 12642595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heregulin-stimulated signaling in rat pheochromocytoma cells. Evidence for ErbB3 interactions with Neu/ErbB2 and p85.
    Gamett DC; Greene T; Wagreich AR; Kim HH; Koland JG; Cerione RA
    J Biol Chem; 1995 Aug; 270(32):19022-7. PubMed ID: 7642563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclic stretch activates p38 SAPK2-, ErbB2-, and AT1-dependent signaling in bladder smooth muscle cells.
    Nguyen HT; Adam RM; Bride SH; Park JM; Peters CA; Freeman MR
    Am J Physiol Cell Physiol; 2000 Oct; 279(4):C1155-67. PubMed ID: 11003596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heregulin (HRG)-induced mitogenic signaling and cytotoxic activity of a HRG/PE40 ligand toxin in human breast cancer cells.
    Fiddes RJ; Janes PW; Sanderson GM; Sivertsen SP; Sutherland RL; Daly RJ
    Cell Growth Differ; 1995 Dec; 6(12):1567-77. PubMed ID: 9019162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.
    Stoica GE; Franke TF; Moroni M; Mueller S; Morgan E; Iann MC; Winder AD; Reiter R; Wellstein A; Martin MB; Stoica A
    Oncogene; 2003 Sep; 22(39):7998-8011. PubMed ID: 12970748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.